Exosomes News and Research

RSS

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints.

19 Aug 2014

Researchers develop new lung-on-chip model for laboratory studies of respiratory challenges

Researchers at RTI International, in collaboration with the University of North Carolina at Chapel Hill, have developed a new lung-on-chip microdevice for laboratory studies of respiratory challenges and therapeutics. The microdevice includes multiple vertically stacked cellular layers that mimic the structure of the airway tissue.

15 Aug 2014

New therapeutic strategy to combat common genetic risk factor for ALS, FTD

A team of researchers at Mayo Clinic and The Scripps Research Institute in Florida have developed a new therapeutic strategy to combat the most common genetic risk factor for the neurodegenerative disorders amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and frontotemporal dementia (FTD).

15 Aug 2014

New technique for studying lifecycle of hepatitis B virus can help develop cure for disease

A new technique for studying the lifecycle of the hepatitis B virus could help researchers develop a cure for the disease.

5 Aug 2014

5-LO enzyme plays important role in the survival of leukaemic AML stem cells

Despite improved therapy, only one out of every two adult patients survive acute myeloid leukaemia (AML). The mean survival time for this disease, which predominantly occurs in the elderly, is less than a year for patients over 65 years. It is assumed that leukaemic stem cells, which cannot be completely eliminated during treatment, are the origin of relapse.

4 Aug 2014

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).

4 Aug 2014

Norovirus vaccines: an interview with Dr Benjamin Lopman, Centers for Disease Control and Prevention, USA

Noroviruses are a group of viruses. They're the leading cause of gastroenteritis, which causes diarrhea and vomiting. They affect the whole age range from young children to the elderly, and, in the US, they cause about 20 million cases annually.

28 Jul 2014

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

25 Jul 2014

New tools for detecting and monitoring TB in captive elephants

Mycobacterium tuberculosis, the organism that causes tuberculosis in humans, also afflicts Asian (and occasionally other) elephants. Diagnosing and treating elephants with TB is a challenge, however, as little is known about how their immune systems respond to the infection.

16 Jul 2014

Study pinpoints molecular cause of cachexia, hints at a potential treatment

New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle occurring in about half of all cancer patients, raising their risk of death, according to scientists from Dana-Farber Cancer Institute.

14 Jul 2014

Immune marker predicts infection risk in critically ill children with traumatic injuries

Researchers studying critically ill children with traumatic injuries have identified an immune marker that predicts which patients are likely to develop a hospital-acquired infection.

10 Jul 2014

FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

Protein Sciences Corporation announced today that the FDA has approved the Company's strain change amendment for its seasonal influenza vaccine, Flublok.

9 Jul 2014

NCL collaborates with PeptiMed to evaluate safety and efficacy of nanocomplex materials

PeptiMed announced today that under a Material Transfer Agreement it will collaborate with the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), located at the Frederick National Laboratory of Cancer Research in Frederick, MD.

23 Jun 2014

High-volume deep well plates available from Porvair Sciences

Precisely manufactured to SLAS/ANSI specifications - Porvair Sciences 24-well deep well plates permit users to simply undertake multiple, high volume (10ml / well) experiments in a single unit maximising both productivity and operational flexibility.

From Chromatrap® - Porvair Sciences Ltd 12 Jun 2014

Scientists discover important new biomarker that could improve HER2 targeted cancer treatments

Scientists from the School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin have made a significant discovery of a new biomarker which may help overcome resistance to newer and more targeted anti-cancer drugs, such as Herceptin, for HER2 positive cancers. These findings may also help the early identification of patients who will benefit more from these treatments.

11 Jun 2014

Eppendorf announces new addition to BioBLU Single-use Vessel Adaptor Kit portfolio

Eppendorf is proud to announce a new addition to the BioBLU Single-use Vessel Adaptor Kit portfolio. The BioBLU 5c and 14c Adaptor Kits allow BioBLU 5c and 14c Single-use vessels to be used on and controlled by Sartorius® BioStat® B-DCU-II controllers (Heat Blanket configuration only).

3 Jun 2014

Novel incubator microscope ideally suited for time-lapse examination

Biologists and doctors rely heavily on incubators and microscopes. Now the Fraunhofer Institute for Biomedical Engineering IBMT has come up with a novel solution that combines the functions of both these tools in a compact and extremely small-scale system.

31 May 2014

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).

31 May 2014

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Protein Sciences Corporation announced today that Astellas Pharma has submitted an application for marketing approval of recombinant influenza HA vaccine ASP7374 (marketed as Flublok® in the United States by Protein Sciences) to the Ministry of Health, Labour and Welfare in Japan for the prevention of influenza.

31 May 2014

Gene regulation responsible for normal breast tissue may also play role in cancer development

About one in eight women in the United States will contract breast cancer in her lifetime. Now new research from Tel Aviv University-affiliated researchers, in collaboration with Johns Hopkins University, has provided another tool to help women, clinicians, and scientists searching for a cure to the one of the most widespread yet incurable diseases on the planet.

30 May 2014

Exosomes News and Research

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Researchers develop new lung-on-chip model for laboratory studies of respiratory challenges

New therapeutic strategy to combat common genetic risk factor for ALS, FTD

New technique for studying lifecycle of hepatitis B virus can help develop cure for disease

5-LO enzyme plays important role in the survival of leukaemic AML stem cells

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Norovirus vaccines: an interview with Dr Benjamin Lopman, Centers for Disease Control and Prevention, USA

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

New tools for detecting and monitoring TB in captive elephants

Study pinpoints molecular cause of cachexia, hints at a potential treatment

Immune marker predicts infection risk in critically ill children with traumatic injuries

FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

NCL collaborates with PeptiMed to evaluate safety and efficacy of nanocomplex materials

High-volume deep well plates available from Porvair Sciences

Scientists discover important new biomarker that could improve HER2 targeted cancer treatments

Eppendorf announces new addition to BioBLU Single-use Vessel Adaptor Kit portfolio

Novel incubator microscope ideally suited for time-lapse examination

Amgen presents extended analysis of PEAK study data at ASCO

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Gene regulation responsible for normal breast tissue may also play role in cancer development

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring